Stage 4 liver disease, commonly called cirrhosis, has a wide survival range depending on whether the liver is still functioning reasonably well or has started to fail. People with compensated cirrhosis (where the liver is scarred but still working) have a median survival of over 12 years. Once the disease progresses to decompensated cirrhosis, where serious complications appear, median survival drops to roughly 2 years without a transplant.
Compensated vs. Decompensated Cirrhosis
The single biggest factor in how long someone lives with stage 4 liver disease is whether the liver has decompensated. In compensated cirrhosis, the liver is heavily scarred but still manages its essential jobs: filtering toxins, producing clotting factors, and processing nutrients. Many people at this stage feel relatively normal and may not even know they have cirrhosis. Median survival in this group exceeds 12 years, and some people live much longer.
Decompensation means the liver can no longer keep up. It announces itself through specific complications: fluid buildup in the abdomen (ascites), vomiting blood from swollen veins in the esophagus, yellowing of the skin and eyes, or confusion caused by toxins the liver can no longer clear. Once any of these appear, the disease has entered a fundamentally different phase. One study tracking both groups found a median survival of about 6.5 years for decompensated patients, though other data puts it closer to 2 years for more advanced cases. The range is wide because decompensation itself exists on a spectrum.
How Doctors Estimate Survival
Two scoring systems help predict outcomes. The Child-Pugh classification sorts patients into three classes based on lab values and symptoms. Class A patients have one-year survival near 100% and two-year survival around 85%. Class B drops to about 80% at one year and 60% at two years. Class C, the most severe, carries roughly 45% one-year survival and 35% at two years.
The MELD score (Model for End-Stage Liver Disease) uses blood tests to estimate 90-day mortality and determine transplant priority. The numbers are stark at higher scores: a MELD below 9 carries only a 1.9% chance of dying within 90 days. A score between 20 and 29 raises that to about 20%. Between 30 and 39, the 90-day mortality jumps to nearly 53%, and above 40 it reaches 71%. If your doctor mentions a MELD score, it tells you a lot about how urgent the situation is.
What Causes the Liver Disease Matters
The underlying reason for cirrhosis influences the outlook, though perhaps less dramatically than many people expect. Five-year survival for compensated alcoholic cirrhosis is around 84%, while decompensated alcoholic cirrhosis drops to about 71%. Cirrhosis from fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease) and hepatitis C show similar five-year survival rates of roughly 75% when matched for disease severity. Overall mortality rates between alcohol-related and fatty liver disease are comparable, though the specific complications that ultimately cause death differ somewhat between the two.
The more important distinction is whether the underlying cause can be treated or removed. Curing hepatitis C with antiviral therapy can stabilize or even partially reverse liver damage. Addressing the metabolic factors behind fatty liver disease, such as weight, blood sugar, and cholesterol, can slow progression. And for alcohol-related cirrhosis, quitting drinking has a measurable impact on survival.
How Quitting Alcohol Changes the Timeline
For people with alcohol-related cirrhosis, abstinence is the most powerful intervention available short of transplant. A retrospective study comparing patients who stopped drinking with those who continued found striking differences in the first few years. At one year, 68% of those who quit were alive compared to 91% of those still drinking. That seems counterintuitive, but it reflects something important: people who quit often do so because they’re already sicker. The drinking group initially included many people with milder disease.
The longer-term picture tells the real story. Survival in the abstaining group stabilized from year three onward, plateauing at about 51%. The drinking group’s survival kept declining year after year, eventually converging at 56% by year six and continuing to fall. The data suggests that at least two years of complete abstinence is needed to see sustained survival benefits. For people who keep drinking, the trajectory only goes one direction.
Complications That Shorten Survival
Specific complications carry their own mortality risks on top of the baseline prognosis. Hepatic encephalopathy, the confusion and cognitive changes caused by toxin buildup in the brain, is one of the most serious. After a first episode, overall one-year survival is just 48%, with a median survival under one year. Some patients experience milder forms manageable with medication, while others develop severe episodes requiring hospitalization.
Ascites that stops responding to diuretics, kidney failure triggered by the liver disease (hepatorenal syndrome), and spontaneous infections of abdominal fluid are all markers of very advanced disease. When these complications cluster together, they typically signal a life expectancy of six months or less, which is the threshold used for hospice eligibility. The formal hospice criteria for liver disease require certain lab abnormalities (significantly impaired blood clotting and low albumin levels) plus at least one of these refractory complications.
Liver Transplant Survival
Transplantation dramatically resets the survival clock for people who qualify. According to the Scientific Registry of Transplant Recipients, adults receiving a deceased donor liver transplant have a five-year survival rate of about 80% and a ten-year survival rate around 64%. Living donor transplants perform slightly better, with five-year survival near 84%.
The challenge is qualifying and waiting. Transplant centers evaluate overall health, not just liver function. Active alcohol use, uncontrolled infections, certain cancers, and severe heart or lung disease can disqualify candidates. Most programs require six months of documented sobriety for alcohol-related liver disease, though some have moved toward shorter evaluation periods for selected patients. The MELD score determines your place on the waiting list, with higher scores (sicker patients) receiving priority. The wait itself can be dangerous: roughly 5% of listed patients die or become too sick for transplant before an organ becomes available.
What Affects Your Individual Outlook
Population statistics describe averages, but individual outcomes vary enormously. Several factors push the numbers in one direction or the other:
- Age: Among hospitalized end-stage liver disease patients over 65, nearly half (46%) died within one year and about 65% within three years. Younger patients generally do better.
- Response to treatment: If ascites responds well to diuretics, or if encephalopathy clears with medication, these are signs the liver still has reserve capacity.
- Nutritional status: Malnutrition is extremely common in advanced cirrhosis and independently worsens survival. Adequate protein intake and calorie supplementation make a measurable difference.
- Ongoing liver injury: Continued exposure to whatever caused the cirrhosis, whether alcohol, uncontrolled hepatitis, or metabolic risk factors, accelerates decline. Removing the cause is the single most effective step besides transplant.
- Complications at diagnosis: Someone diagnosed at the compensated stage has years to manage the disease. Someone diagnosed only after a major bleed or encephalopathy episode is already in a more precarious position.
The gap between best-case and worst-case scenarios in stage 4 liver disease is wider than in most chronic conditions. A person with well-managed compensated cirrhosis may live a relatively normal lifespan. A person with decompensated disease, a high MELD score, and complications like encephalopathy may have months. Where someone falls on that spectrum depends on how much functional liver remains, how aggressively the underlying cause is addressed, and whether transplant is an option.